Compare Ascendis Pharma A/S (ASND) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Real Estate Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Vanguard Real Estate Index Fund ETF trades at $97.34. Which is the better fit depends on your goals.
| ASND | VNQ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $98.66 |
52-Week Low | $163.32 | $87.00 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VNQ trades at $97.32, up 0.24% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 56.24, while recent news highlights REIT sector resilience amid interest rate pressures. Support levels cluster around $96-97 with resistance at $98.
The REIT ETF faces headwinds from elevated interest rates but benefits from steady dividend income and sector recovery signs. Key risks include Fed policy uncertainty and inflation persistence, while institutional sentiment remains cautiously optimistic about real estate fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
